Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase NA 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 85Terminated 29Recruiting 9Unknown 7Active not recruiting 3Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms 57Breast Neoplasms 52Leukemia, Myeloid, Acute 40Carcinoma, Non-Small-Cell Lung 40Lymphoma 35Pancreatic Neoplasms 30Leukemia, Lymphocytic, Chronic, B-Cell 30Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Neoplasm Metastasis 27Ovarian Neoplasms 25Multiple Myeloma 25Lymphoma, Non-Hodgkin 25Recurrence 24Lung Neoplasms 23Melanoma 22Lymphoma, Large B-Cell, Diffuse 21Prostatic Neoplasms 20Glioblastoma 20Brain Neoplasms 19Colorectal Neoplasms 18Lymphoma, Follicular 17Squamous Cell Carcinoma of Head and Neck 16Sarcoma 16Lymphoma, B-Cell 15Lymphoma, Mantle-Cell 14Myelodysplastic Syndromes 13Urinary Bladder Neoplasms 12Lymphoma, B-Cell, Marginal Zone 12Glioma 12

Interventions

Melphalan 1Bortezomib 1Arsenic Trioxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Neoplasms, Plasma Cell × Clear all
NCT00504101 2016-12-15

Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma

University of Miami

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡